Kalderos has raised $43.0M in total across 2 funding rounds.
Kalderos's investors include Alumni Ventures, Tribe Capital, Uprising, Matt Mazzeo, Bain Capital Ventures.
Kalderos is a healthcare technology company founded in 2016 that builds the world’s first Drug Discount Management platform. It serves healthcare providers, drug manufacturers, payers, and government agencies by using data infrastructure, artificial intelligence, and machine learning to improve transparency, compliance, and efficiency in drug discount programs such as the 340B program. The platform helps eliminate waste and noncompliance by analyzing claims and facilitating better collaboration among stakeholders. Kalderos has processed over 1 million claims for approximately 4,200 safety net providers and is experiencing strong growth, with provider engagement increasing 20-fold since 2018 and revenue on track to double in 2022[1][4][6][7].
Kalderos was founded in 2016 in Chicago by a team focused on solving systemic inefficiencies in the U.S. healthcare drug discount ecosystem. The founders identified the complexity and opacity in drug discount programs, which led to costly noncompliance and disputes. They developed a technology platform leveraging big data and AI to bring transparency, trust, and equity to drug discount management. Early traction came from successfully enabling safety net providers and manufacturers to communicate more effectively and resolve compliance issues, positioning Kalderos as a pioneer in this niche healthcare technology space[1][4][6].
Kalderos rides the growing trend of applying AI and big data analytics to healthcare administration, particularly in drug pricing and compliance—a sector plagued by complexity and inefficiency. The timing is critical as regulatory scrutiny and healthcare costs rise, increasing demand for transparent, technology-driven solutions. By enabling better collaboration and compliance in drug discount programs, Kalderos helps reduce waste and fraud, contributing to a more sustainable healthcare system. Its platform influences the broader ecosystem by setting new standards for data sharing and operational transparency among diverse healthcare stakeholders[1][4][6].
Kalderos is poised to expand its influence as healthcare systems increasingly adopt AI-driven compliance and financial management tools. Future growth will likely be shaped by ongoing regulatory changes, increasing demand for transparency in drug pricing, and broader adoption of cloud-based healthcare solutions. The company’s continued innovation in AI and collaboration tools positions it to deepen its impact on drug discount programs and potentially expand into related healthcare financial management areas. As Kalderos scales, it may become a critical infrastructure provider for drug discount compliance, helping the healthcare industry focus more on patient outcomes rather than administrative dysfunction[1][4][6][7].
Kalderos has raised $43.0M across 2 funding rounds. Most recently, it raised $15.0M Venture Round in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $15.0M Venture Round | Alumni Ventures, Tribe Capital, Uprising, Matt Mazzeo | |
| Jun 1, 2020 | $28.0M Series B | Bain Capital Ventures |
